Eli Lilly has appointed Anne-Virginie Eggimann as the new chief development officer for its regenerative medicine unit, a strategic move aimed at bolstering its capabilities in this rapidly evolving field. Eggimann previously served at Flagship Pioneering and bluebird bio, where she honed her expertise in developing innovative therapies over the past three and a half years.
This appointment comes at a time when the regenerative medicine sector is gaining momentum, driven by advancements in gene editing and cell therapies. Lilly’s decision to bring in a seasoned leader like Eggimann signals its commitment to enhancing its portfolio in regenerative therapies, which are increasingly viewed as critical for addressing unmet medical needs.
The implications for the industry are significant, as Lilly seeks to position itself as a leader in regenerative medicine. This could lead to increased competition in the sector, prompting other firms to accelerate their own development efforts and partnerships, ultimately benefiting patients through more innovative treatment options.
Open the full market picture for your next decision →
